214 related articles for article (PubMed ID: 35275285)
41. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.
Reeder-Hayes KE; Meyer AM; Dusetzina SB; Liu H; Wheeler SB
Breast Cancer Res Treat; 2014 Jun; 145(3):743-51. PubMed ID: 24789443
[TBL] [Abstract][Full Text] [Related]
42. Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors.
Bedi JS; Mayo RM; Chen L; Dickes L; Sherrill WW; Jones K
J Oncol Pharm Pract; 2020 Jan; 26(1):36-42. PubMed ID: 30885081
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular Disease After Aromatase Inhibitor Use.
Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
[TBL] [Abstract][Full Text] [Related]
44. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
van Herk-Sukel MP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Coebergh JW; Herings RM
Breast Cancer Res Treat; 2010 Aug; 122(3):843-51. PubMed ID: 20058066
[TBL] [Abstract][Full Text] [Related]
45. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
[TBL] [Abstract][Full Text] [Related]
46. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
47. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
48. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.
Aiello EJ; Buist DS; Wagner EH; Tuzzio L; Greene SM; Lamerato LE; Field TS; Herrinton LJ; Haque R; Hart G; Bischoff KJ; Geiger AM
Breast Cancer Res Treat; 2008 Feb; 107(3):397-403. PubMed ID: 17393300
[TBL] [Abstract][Full Text] [Related]
49. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
50. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
51. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
52. Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D.
Charlson JA; McGinley EL; Nattinger AB; Neuner JM; Pezzin LE
J Natl Compr Canc Netw; 2017 Dec; 15(12):1509-1517. PubMed ID: 29223989
[No Abstract] [Full Text] [Related]
53. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
54. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
[TBL] [Abstract][Full Text] [Related]
55. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Jiang M; Chen W; Hu Y; Chen C; Li H
Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958
[TBL] [Abstract][Full Text] [Related]
57. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
58. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
59. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S; Sedrak MS; Kimmick GG
Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
[TBL] [Abstract][Full Text] [Related]
60. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]